TNF alpha ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
271	強直性脊椎炎	3

271. 強直性脊椎炎

---

臨床試験数 : 574 /  薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01361542 (ClinicalTrials.gov)	February 2011	24/5/2011	Effect Of Anti TNF Alpha Therapy And Their Adverse Effects In Ankylosing Spondylitis In A North Indian Population	Effect Of Anti TNF Alpha Therapy On Disease Activity And Bone Health, And Their Adverse Effects In Ankylosing Spondylitis In A North Indian Population	Ankylosing Spondylitis	Drug: anti TNF alpha agent;Drug: Anti TNF alpha therapy	All India Institute of Medical Sciences, New Delhi	NULL	Completed	18 Years	55 Years	Both	24	N/A	India
2	NCT02456363 (ClinicalTrials.gov)	November 2009	14/12/2014	Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis	Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis—A Registry Project	Ankylosing Spondylitis	Biological: TNF alpha;Drug: NSAIDs and sulfasalazine	Chung Shan Medical University	NULL	Recruiting	18 Years	N/A	Both	300	Phase 2	Taiwan
3	EUCTR2006-002306-64-DE (EUCTR)	28/12/2006	04/10/2006	Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab - Ritux-AS-01	Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab - Ritux-AS-01	Moderate to severe ankylosing spondylitis who have had an inadequate response to or do not tolerate conventional therapy including NSAIDs, DMARDs and TNF alpha inhibitors	Trade Name: Rituximab/ Mabthera Product Name: MabThera Product Code: Ro45-2294 INN or Proposed INN: rituximab	Charité Universitaetsmedizin	NULL	Not Recruiting			Female: yes Male: yes			Germany